期刊
TRENDS IN NEUROSCIENCES
卷 44, 期 4, 页码 260-275出版社
CELL PRESS
DOI: 10.1016/j.tins.2020.11.008
关键词
-
资金
- Yale Center for Psychedelic Science, National Institutes of Health (NIH) /NIMH (National Institute of Mental Health) [R01MH112750, R01MH121848]
- Simons Foundation Autism Research Initiative Pilot Award
- NIH/NIGMS (National Institute of General Medical Sciences) Medical Scientist Training grant [T32GM007205]
Studies have shown that serotonergic psychedelics like psilocybin and ketamine may relieve depression by promoting neural plasticity. Despite targeting distinct molecular receptors in the brain, the behavioral and neural effects of these compounds are similar, possibly by enhancing and suppressing membrane excitability at dendrites.
Pilot studies have hinted that serotonergic psychedelics such as psilocybin may relieve depression, and could possibly do so by promoting neural plasticity. Intriguingly, another psychotomimetic compound, ketamine, is a fast-acting antidepressant and induces synapse formation. The similarities in behavioral and neural effects have been puzzling because the compounds target distinct molecular receptors in the brain. In this opinion article, we develop a conceptual framework that suggests the actions of ketamine and serotonergic psychedelics may converge at the dendrites, to both enhance and suppress membrane excitability. We speculate that mismatches in the opposing actions on dendritic excitability may relate to these compounds? cell-type and region selectivity, their moderate range of effects and toxicity, and their plasticity-promoting capacities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据